vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease. Its drug candidates also include TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase 2b clinical trials for the treatment of type 2 diabetes, as well as initiated Phase 1b/2 clinical trials for the treatment of type 1 diabetes; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. vTv Therapeutics Inc. has a license and research agreement with Calithera Biosciences, Inc. to develop and commercialize its hexokinase II inhibitors for therapeutic, prophylactic, preventative, or diagnostic use. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of vTv Therapeutics Holdings LLC.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone336-841-0300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$290,000.00
Profitability
Miscellaneous
Employees56
OptionableNot Optionable
vTv Therapeutics (NASDAQ:VTVT) Frequently Asked Questions
What is vTv Therapeutics' stock symbol?
vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT."
How were vTv Therapeutics' earnings last quarter?
vTv Therapeutics Inc (NASDAQ:VTVT) issued its quarterly earnings data on Thursday, November, 8th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.12) by $0.06. The biotechnology company earned $3.38 million during the quarter, compared to the consensus estimate of $2.06 million. View vTv Therapeutics' Earnings History.
When is vTv Therapeutics' next earnings date?
What price target have analysts set for VTVT?
5 brokerages have issued 1 year price targets for vTv Therapeutics' stock. Their forecasts range from $4.00 to $28.00. On average, they anticipate vTv Therapeutics' stock price to reach $15.75 in the next year. This suggests a possible upside of 479.0% from the stock's current price. View Analyst Price Targets for vTv Therapeutics.
What is the consensus analysts' recommendation for vTv Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for vTv Therapeutics in the last year. There are currently 5 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for vTv Therapeutics.
Has vTv Therapeutics been receiving favorable news coverage?
Media headlines about VTVT stock have trended somewhat positive recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. vTv Therapeutics earned a news sentiment score of 0.7 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days.
Who are some of vTv Therapeutics' key competitors?
Some companies that are related to vTv Therapeutics include GlycoMimetics (GLYC), Arcus Biosciences (RCUS), Corium International (CORI), Akorn (AKRX), Corbus Pharmaceuticals (CRBP), ZEALAND PHARMA/S (ZEAL), Odonate Therapeutics (ODT), Clementia Pharmaceuticals (CMTA), Evolus (EOLS), Kezar Life Sciences (KZR), Beyondspring (BYSI), ArQule (ARQL), Progenics Pharmaceuticals (PGNX), Evelo Biosciences (EVLO) and MediciNova (MNOV).
Who are vTv Therapeutics' key executives?
vTv Therapeutics' management team includes the folowing people:
- Mr. Jeffrey B. Kindler, Exec. Chairman (Age 63)
- Mr. Stephen L. Holcombe, Pres & CEO (Age 62)
- Mr. Rudy C. Howard CPA, B.A., CPA, Exec. VP & CFO (Age 61)
- Dr. Carmen Valcarce Ph.D., Chief Scientific Officer & Exec. VP
- Ms. Robin E. Abrams, Exec. VP & Gen. Counsel (Age 55)
When did vTv Therapeutics IPO?
(VTVT) raised $125 million in an initial public offering (IPO) on Thursday, July 30th 2015. The company issued 7,800,000 shares at $15.00-$17.00 per share. Piper Jaffray and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.
How do I buy shares of vTv Therapeutics?
Shares of VTVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is vTv Therapeutics' stock price today?
One share of VTVT stock can currently be purchased for approximately $2.72.
How big of a company is vTv Therapeutics?
vTv Therapeutics has a market capitalization of $115.31 million and generates $290,000.00 in revenue each year. The biotechnology company earns $-16,140,000.00 in net income (profit) each year or ($1.67) on an earnings per share basis. vTv Therapeutics employs 56 workers across the globe.
What is vTv Therapeutics' official website?
How can I contact vTv Therapeutics?
vTv Therapeutics' mailing address is 4170 MENDENHALL OAKS PKWY, HIGH POINT NC, 27265. The biotechnology company can be reached via phone at 336-841-0300 or via email at [email protected]
MarketBeat Community Rating for vTv Therapeutics (NASDAQ VTVT)
MarketBeat's community ratings are surveys of what our community members think about vTv Therapeutics and other stocks. Vote "Outperform" if you believe VTVT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VTVT will underperform the S&P 500 over the long term. You may vote once every thirty days.
